institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 3 days ago • loading... • Updated 3 days ago

Gameto's $44M Series C to Help Redefine Reproductive Care, as First Patients Recruited for Pivotal Stem Cell Phase 3 Trial

Summary by PR Newswire

/PRNewswire/ -- Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, today announced the completion...

10 Articles

10 Articles

+9 Reposted by 9 other sources

Gameto's $44M Series C to Help Redefine Reproductive Care, as First Patients Recruited for Pivotal Stem Cell Phase 3 Trial

As birth rates decline and US IVF access falls further behind, Gameto recruits first Phase 3 patients for cutting-edge biotechnology to reignite reproductive health possibilitiesCompany's $127 million in total funding represents one of the largest investment in reproductive US biopharma…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources10

Leaning Left0Leaning Right0Center4Last Updated2 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 3 days ago on Tuesday, August 12, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics